Systematic Review Of Shenling Baizhu San In The Treatment Of Ulcerative Colitis

Objectives To evaluate the clinical efficacy and safety of Shenlingbaizhu powder in the treatment of ulcerative colitis(UC)by means of evidence-based medicine.Methods 1 Document inclusion criteria: 1)Type of study: randomized controlled trial(RCT),regardless of whether or not blindness is used 2)Language type: Language limited to Chinese / English.3)Subjects: In the literature,the selection criteria included in the literature were in line with the diagnostic criteria of UC for the diagnosis and treatment of inflammatory bowel disease approved by the Chinese Medical Association of Infectious Diseases in 2012 [1] Of patients,sex,age,case source.4)Interventions:(1)The treatment group was treated with Shenlingbaizhu San(including the addition and subtraction of the drug taste and the dosage according to the traditional Chinese medicine).The control group was treated with placebo or western medicine or blank control.(2)the treatment group in the control group based on the means of treatment plus Shenlingbaizhu powder addition and subtraction;the control group to give Western medicine therapy.5)outcome indicators:(1)treatment of invalid number(2)Sutherland disease activity index(DAI)score.(IL-17),IL-23,tumor necrosis factor-?(TNF-?)and C-reactive protein(CRP)levels;(4)the probability of recurrence(5)whether the drug is safe,Produce side effects,or reactions that are unrelated to the purpose of the drug.2 Search: 1)Search scope: CNKI,Vibu database,Wanfang database,CBMdisc;and Cochrane Library,PUBMED database.2)Search time: Since June 2016,all the information on the treatment of UC,including whether public publication,internal information,is being published and other restrictions.3)manual search: manual search information on the citation basis and summary of important meetings at home and abroad.4)search terms and search strategies(1)Chinese search terms: the key words or keywords for ulcerative colitis,inflammatory bowel disease;Shen Ling Atractylodes,Shenlingbaizhu powder,Shenlingbaobao pill,Shen Ling Bai granule Shenlingbaizhu capsules.(2)English search term: ulcerative colitis,inflammatory bowel disease,Idiopathic Proctocolitis,Colitis Gravis,Shenling Baizhu,Shenling Baizhu powder,Shenling Baizhu San,Shenling Baizhu capsule,Shenling Baizhu pill is the key word or keyword.Keywords and keywords are combined into the main way of this search.3 Screening: Two persons screen and select the data according to the criteria of inclusion and exclusion.If the opinion is not uniform,add another member to participate in the discussion and decide whether or not to select the information.4 Data extraction method: EXCEL software is used for data entry,the selected content includes: data number,test economic support source,test location,sample number,subject characteristics(including the criteria to determine the disease,inclusion and exclusion criteria(Name,method of administration,duration of medication,duration of medication),outcome index(primary and secondary outcome indicators,evaluation of the effect of medication),the number of cases,Standard,primary outcome,adverse events),test method characteristics(including randomized grouping methods,random hiding,blindness,data is complete,whether the outcome has been selective reports,etc.).5 Evaluate the quality of the literature using the "Cochrane Risk Bias Assessment Tool" recommended by the Cochrane Collaboration.Which includes seven aspects:(1)random grouping method(2)the intervention method of the allocation of methods to hide the researchers and subjects to hide specific interventions and other information(4)the outcome of the reviewers to hide the specific information(5)whether the explicit report of the interruption test The number of reasons,etc.(6)whether the content is completely reported(7)other possible causes of experimental error.In view of each of the findings,the "7" is judged by "low risk","unknown risk(lack of information or uncertainty)," high risk ".6 Systematic review and meta analysis: The odds ratio(OR)was used to measure the clinical efficacy statistics.The measurement data were calculated using mean difference(MD).95% trusted(CI)to express the effect index.Q statistics and I2 statistics were used to determine whether the characteristics of the study data are different and different.When P> 0.10,I2 <50%,indicating the data between the(P <0.10,I2> 50%),to find out the reasons for this difference,such as divided into different groups or in different groups or the same type of data,given the same nature of the data,given the fixed effect model;Change the entry of a study to see the effect of changes in the situation and other methods,and strive to reduce or eliminate the heterogeneity of the reasons.If the above practice still can not solve the heterogeneity,then give the random effect model to solve If the difference is too large,the effect of the results or the merger has no practical significance,it is changed to the general statistical narrative analysis.The hopper map is used to detect whether there is publication bias.Results 1 Results: Shenlingbaizhu powder in reducing the number of patients with UC ineffective,inflammatory factors IL-17,IL-23,TNF-a levels,recurrence,and improve the patient's CRP,DAI score better than Western medicine,the difference in statistics(P <0.05).2 safety assessment: a study of Shenlingbaizhu San treatment of UC is described in the safety.The results showed no serious adverse reactions.Conclusions 1 Shenlingbaizhu powder treatment of UC,and Western medicine treatment means compared to reduce the number of invalid,improve the DAI score,reduce the inflammatory indicators of CRP,inflammatory factors IL-17,IL-23,TNF-a degree,reduce the disease Recurrence.2 due to the elaborated research data is too small,failed to clear the safety and long-term effect of Shenlingbaizhu San treatment of UC.3 SR included in the study of the existence of bias risk,the quality level is not high,affecting the above conclusions of evidence-based evidence of medical strength.Will be in the future with more high-quality multi-center,random,double-blind,large sample of RCT production,to further improve the SR,in order to Shen Ling Baizhi San treatment of UC effectiveness and safety to provide higher evidence-based Medical evidence.